Summary

Report Scope
This report on the global market for AI in pharmaceuticals explores market dynamics and trends, and analyzes technological developments, software performance, clinical trials, new product approvals and emerging technologies. The report also includes profiles of leading companies and their strategies.
The report explores how AI is transforming the pharmaceutical industry through enhanced diagnostic capabilities, early disease detection, clinical trial optimization, drug discovery and personalized treatment planning. It also examines AI disruption across industry verticals and value chain stages, while presenting market spending patterns, investment forecasts, R&D expenditures and venture capital funding. The report segments the market by product type, application and region. Types include software and services. Applications include drug discovery and development, clinical trials, personalized medicines and others. The four regions covered are North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data has been provided for 2024 as the base year, with forecasts for 2025 through 2030.
Report Includes
- 27 data tables and 62 additional tables
- An analysis of the global markets for artificial intelligence (AI) in the pharmaceuticals industry
- Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
- Estimates of the market’s size and revenue growth prospects, accompanied by a market share analysis by product type, application and region
- Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
- Insights derived from Porter’s Five Forces model, as well as a global supply chain analysis
- Case studies on AI implementation to streamline processes across drug discovery and development, manufacturing, quality control and patient care
- A relevant patent analysis, featuring key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Google DeepMind, Atomwise Inc., Insilico Medicine, Recursion Pharmaceuticals and Nvidia Corp.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Current Market Overview
Macroeconomic Factors Analysis
Government Policy and Regulation
Technological Infrastructure and Digital Readiness
Global Trade and Supply Chain Dynamics
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Potential for New Entrants (Moderate to High)
Bargaining Power of Suppliers (Low to Moderate)
Bargaining Power of Buyers (High)
Threat of Substitute Products or Services (Low to Moderate)
Industry Level of Competitiveness (High)
AI's Impact on the Pharmaceutical Value Chain
Drug Discovery and Preclinical Development: Accelerated Innovation
Clinical Trials: Smarter Design and Execution
Manufacturing and Supply Chain: Intelligent Operations
Regulatory Affairs and Compliance: Automation and Accuracy
Commercialization and Market Access: Data-Driven Strategies
Post-Market Surveillance: Continuous Learning and Safety Monitoring
Use Cases
Use Case 1: Generative AI for Efficiency in Regulatory Submissions
Use Case 2: Generative AI-Enabled R&D Assistant for Synthesis Routes
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Faster Drug Discovery and Development
Increasing Adoption of AI in Clinical Trials
Demand for Precision Medicine and AI Applications
Market Restraints
Regulatory and Ethical Concerns
Data Challenges
Market Opportunities
Collaborations and Investments
Increased Focus on Drug Discovery in Emerging Nations
Advances of Generative AI in Molecular Design
Chapter 4 Regulatory Landscape
Overview
Regulatory Scenario in the U.S.
Regulatory Scenario in Europe
Regulatory Scenario in Japan
Regulatory Scenario in China
Other Countries
Chapter 5 Emerging Trends and Pipeline Analysis
Emerging Trends
Generative AI in Pharma
Federated Learning
Natural Language Processing
Generative Adversarial Networks
Pipeline Analysis
Takeaways
Patent Analysis
Findings
Chapter 6 Market Segment Analysis
Segmentation Breakdown
Market Breakdown, by Product Type
Takeaways
Software
Services
Market Breakdown, by Application
Takeaways
Drug Discovery and Development
Clinical Trials
Personalized Medicine
Other Applications
Geographic Breakdown
Market Breakdown, by Region
Takeaways
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 7 Competitive Intelligence
Takeaways
Competitive Analysis
Strategic Analysis
Investment Landscape
Chapter 8 Sustainability in AI in the Pharmaceutical Industry: ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives
ESG Risk Ratings
Concluding Remarks from BCC Research
Chapter 9 Appendix
Research Methodology
Sources
Abbreviations
Company Profiles
AICURE
ATOMWISE INC.
BENEVOLENTAI
GOOGLE DEEPMIND
HEALX
IKTOS
INSILICO MEDICINE
INVENIAI LLC.
NVIDIA CORP.
PATHAI INC.
RECURSION
SCHRODINGER INC.
SYRENCLOUD INC.
TEMPUS AI INC.
XTALPI INC.
Emerging Start-ups/Market Disruptors